Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Nov;37(11):2261–2264. doi: 10.1128/aac.37.11.2261

Azithromycin inhibition of intracellular Legionella micdadei.

G R Donowitz 1, K I Earnhardt 1
PMCID: PMC192376  PMID: 8285604

Abstract

Legionella micdadei is an intracellular parasite that is ingested, but not killed, by leukocytes. Within monocytes, the organism has been shown to grow 1.0 to 2.0 log10 units over 48 h (D. L. Weinbaum, R. R. Benner, J. N. Dowling, A. Alpern, A. W. Pasculle, and G. R. Donowitz, Infect. Immun. 46:68-73, 1984). Intracellular L. micdadei would appear to be a useful model in which to study the effect of antibiotics which accumulate intracellularly. Azithromycin, a newly introduced azalide, is highly concentrated within leukocytes and was therefore studied to determine its effect on a single strain of L. micdadei that had been ingested by human monocytes. Peripheral blood monocytes were allowed to ingest L. micdadei and extracellular, nonadherent organisms were subsequently removed by washing. Cells and cell-associated bacteria were then incubated at 0, 24, and 48 h in media with serial concentrations of azithromycin at sub-MIC levels (less than 1.0 microgram/ml). L. micdadei in cells not exposed to azithromycin grew 0.8 +/- 0.1 log10 units (mean +/- standard deviation) at 24 h and 1.7 +/- 0.4 log10 units at 48 h. At both 24 and 48 h, the lowest concentrations of azithromycin tested (0.02 microgram/ml) significantly inhibited bacterial growth in monocytes (P = 0.02). A stepwise inhibition of L. micdadei CFUs was noted with increasing azithromycin concentrations. In contrast, when cells were exposed to antibiotic before ingesting L. micdadei, a less effective antibacterial effect was noted. Under certain in vitro conditions, azithromycin is a potent agent against intracellular L. micdadei.

Full text

PDF
2261

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson R., Joone G., van Rensburg C. E. An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. J Antimicrob Chemother. 1988 Dec;22(6):923–933. doi: 10.1093/jac/22.6.923. [DOI] [PubMed] [Google Scholar]
  2. Anderson R., Van Rensburg C. E., Jooné G., Lukey P. T. An in-vitro comparison of the intraphagocytic bioactivity of erythromycin and roxithromycin. J Antimicrob Chemother. 1987 Nov;20 (Suppl B):57–68. doi: 10.1093/jac/20.suppl_b.57. [DOI] [PubMed] [Google Scholar]
  3. Bornstein N., Roudier C., Fleurette J. Determination of the activity on Legionella of eight macrolides and related agents by comparative testing on three media. J Antimicrob Chemother. 1985 Jan;15(1):17–22. doi: 10.1093/jac/15.1.17. [DOI] [PubMed] [Google Scholar]
  4. Donowitz G. R., Mandell G. L. Monocyte function in patients with chronic granulomatous disease of childhood. Blood. 1982 Nov;60(5):1151–1158. [PubMed] [Google Scholar]
  5. Fitzgeorge R. B., Featherstone A. S., Baskerville A. Efficacy of azithromycin in the treatment of guinea pigs infected with Legionella pneumophila by aerosol. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):101–108. doi: 10.1093/jac/25.suppl_a.101. [DOI] [PubMed] [Google Scholar]
  6. Girard A. E., Girard D., Retsema J. A. Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection. J Antimicrob Chemother. 1990 Jan;25 (Suppl A):61–71. doi: 10.1093/jac/25.suppl_a.61. [DOI] [PubMed] [Google Scholar]
  7. Gladue R. P., Bright G. M., Isaacson R. E., Newborg M. F. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother. 1989 Mar;33(3):277–282. doi: 10.1128/aac.33.3.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Koga H. High-performance liquid chromatography measurement of antimicrobial concentrations in polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1987 Dec;31(12):1904–1908. doi: 10.1128/aac.31.12.1904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Morrill W. E., Barbaree J. M., Fields B. S., Sanden G. N., Martin W. T. Increased recovery of Legionella micdadei and Legionella bozemanii on buffered charcoal yeast extract agar supplemented with albumin. J Clin Microbiol. 1990 Mar;28(3):616–618. doi: 10.1128/jcm.28.3.616-618.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Myerowitz R. L., Pasculle A. W., Dowling J. N., Pazin G. J., Sr, Puerzer M., Yee R. B., Rinaldo C. R., Jr, Hakala T. R. Opportunistic lung infection due to "Pittsburgh Pneumonia Agent". N Engl J Med. 1979 Nov 1;301(18):953–958. doi: 10.1056/NEJM197911013011801. [DOI] [PubMed] [Google Scholar]
  11. Pasculle A. W., Dowling J. N., Weyant R. S., Sniffen J. M., Cordes L. G., Gorman G. M., Feeley J. C. Susceptibility of Pittsburgh pneumonia agent (Legionella micdadei) and other newly recognized members of the genus Legionella to nineteen antimicrobial agents. Antimicrob Agents Chemother. 1981 Dec;20(6):793–799. doi: 10.1128/aac.20.6.793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pasculle A. W., Feeley J. C., Gibson R. J., Cordes L. G., Myerowitz R. L., Patton C. M., Gorman G. W., Carmack C. L., Ezzell J. W., Dowling J. N. Pittsburgh pneumonia agent: direct isolation from human lung tissue. J Infect Dis. 1980 Jun;141(6):727–732. doi: 10.1093/infdis/141.6.727. [DOI] [PubMed] [Google Scholar]
  13. Prokesch R. C., Hand W. L. Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1982 Mar;21(3):373–380. doi: 10.1128/aac.21.3.373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Retsema J., Girard A., Schelkly W., Manousos M., Anderson M., Bright G., Borovoy R., Brennan L., Mason R. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother. 1987 Dec;31(12):1939–1947. doi: 10.1128/aac.31.12.1939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Rogers B. H., Donowitz G. R., Walker G. K., Harding S. A., Sande M. A. Opportunistic pneumonia: a clinicopathological study of five cases caused by an unidentified acid-fast bacterium. N Engl J Med. 1979 Nov 1;301(18):959–961. doi: 10.1056/NEJM197911013011802. [DOI] [PubMed] [Google Scholar]
  16. Schentag J. J., Ballow C. H. Tissue-directed pharmacokinetics. Am J Med. 1991 Sep 12;91(3A):5S–11S. doi: 10.1016/0002-9343(91)90394-d. [DOI] [PubMed] [Google Scholar]
  17. Tulkens P. M. Intracellular pharmacokinetics and localization of antibiotics as predictors of their efficacy against intraphagocytic infections. Scand J Infect Dis Suppl. 1990;74:209–217. [PubMed] [Google Scholar]
  18. Weinbaum D. L., Bailey J., Benner R. R., Pasculle A. W., Dowling J. N. The contribution of human neutrophils and serum to host defense against Legionella micdadei. J Infect Dis. 1983 Sep;148(3):510–517. doi: 10.1093/infdis/148.3.510. [DOI] [PubMed] [Google Scholar]
  19. Weinbaum D. L., Benner R. R., Dowling J. N., Alpern A., Pasculle A. W., Donowitz G. R. Interaction of Legionella micdadei with human monocytes. Infect Immun. 1984 Oct;46(1):68–73. doi: 10.1128/iai.46.1.68-73.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Winn W. C., Jr, Myerowitz R. L. The pathology of the Legionella pneumonias. A review of 74 cases and the literature. Hum Pathol. 1981 May;12(5):401–422. doi: 10.1016/s0046-8177(81)80021-4. [DOI] [PubMed] [Google Scholar]
  21. van den Broek P. J. Antimicrobial drugs, microorganisms, and phagocytes. Rev Infect Dis. 1989 Mar-Apr;11(2):213–245. doi: 10.1093/clinids/11.2.213. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES